Beta-Amyloid ELISA Kits (human, mouse/rat)
AnaSpec Beta-Amyloid ELISA Kits Human & Mouse/Rat

Beta-Amyloid ELISA Kits (human, mouse/rat)

One-step assay kits to quantify human or mouse/rat beta-amyloid (1-40) or (1-42) peptides. Our beta-amyloid quantitative ELISA kits are optimized to detect beta-amyloid fragments with high sensitivity, specificity and reproducibility.

Select the kit that’s right for you!

Convenient One-Step Assay Format

  • Pre-coated and pre-blocked 96-well strip plate
  • Ready-to-use substrate solution and other assay components
  • One step assay (samples and detection antibodies are added simultaneously)
  • 1 hour assay time at room temperature (excluding incubation)

High Sensitivity

  • Detects as low as 2 pg/ml (13 fmoles/ml) of human beta-Amyloid (1-40) or (1-42)

Broad Dynamic Range

  • 3.9-250 pg/ml of human beta-Amyloid (1-40) or (1-42) peptide

The kits are optimized to detect human beta-Amyloid (1-40) and (1-42) peptides in human brain lysate, transgenic mouse brain lysate, human cerebrospinal fluid, plasma, or saliva. Wells are pre-coated with monoclonal anti-beta-Amyloid (1-40) or (1-42) specific capture antibodies and blocked with a proprietary blocking solution. The amount of human beta-Amyloid (1-40) or (1-42) is quantified using ELISA. Ample materials and reagents are provided to perform 96 assays.

SensoLyte® Beta-Amyloid ELISA Kits

Product Name
Catalog #
SensoLyte® Anti-Human β-Amyloid (1-40) Quantitative ELISA *Colorimetric*
SensoLyte® Anti-Human β-Amyloid (1-42) Quantitative ELISA *Colorimetric*
SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-40) Quantitative ELISA *Colorimetric*
SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-42) Quantitative ELISA *Colorimetric*

The following is a feedback from Dr. Patrick L. McGeer (Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada):

  • Kits are reliable and simple to use
  • Results are reproducible
Human Aβ40 Standard Curve
Human Aβ40 Standard Curve
Mouse/Rat Aβ40 Standard Curve
Mouse/Rat Standard Curve

Related Products


  • Hidisoglu E, Yargicoglu P. (2020). Auditory evoked potentials might have the potential to serve as early indicators related to amyloid beta peptide toxicity. Advances in Medical Sciences. 65(1):223-32. DOI: 10.1016/j.advms.2020.02.001
  • Bertoldi, K. et al. (2018). Circulating extracellular vesicles in the aging process: impact of aerobic exercise. Mol Cell Biochem. 440, 115–125. DOI:10.1007/s11010-017-3160-4.
  • Yang H, et al. (2018). The effect of chronic cerebral hypoperfusion on amyloid-β metabolism in a transgenic mouse model of Alzheimer's disease (PS1V97L). Journal of Alzheimer's Disease. 62(4):1609-21. DOI:10.3233/JAD-171094.
  • Mohamed LA, et al. (2016). Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1862(4):778-87.
  • Camponova P, et al. (2017). Alteration of high-density lipoprotein functionality in Alzheimer's disease patients. Canadian Journal of Physiology and Pharmacology. 95(8):894-903. DOI:10.1139/cjpp-2016-0710.
  • Zhang, J. et al. (2014). Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's Disease. J Neurosci. 34, 14919. DOI: 10.1523/JNEUROSCI.1165-14.2014.
  • Qosa H, et al. (2014). Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacol. 79:668-678. DOI:10.1016/j.neuropharm.2014.01.023


  1. Levites Y. et al., J Clin Invest 116(1): 193-201: 2006.
  2. Broersen K. et al., Alzheimer's Res Therapy 2: 1-14, 2010.
  3. Zhang Yun-Wu, et al., Mol Brain 4: 1-13: 2011.
  4. Koechling T., et al., Intl J Alzheimer's Dis, 2010.
  5. Bobba A., et al., Intl J Alzheimer's Dis, 2010.
  6. Bermejo-Pareja F., et al., BMC Neurol, 2010.